Factor XIII, clot structure, thrombosis

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Blood coagulation factor XIII (FXIII) is a tetrameric protein consisting of two catalytic A (FXIII-A) and two carrier/inhibitory B (FXIII-B) subunits. It is a zymogen, which becomes transformed into an active transglutaminase (FXIIIa) in the final phase of coagulation cascade by thrombin and Ca 2 +. FXIII is essential for hemostasis, its deficiency results in severe bleeding diathesis. FXIIIa mechanically stabilizes fibrin by cross-linking its α-, and γ-chains. It also protects newly formed fibrin from fibrinolysis, primarily by cross-linking α 2-plasmin inhibitor to fibrin. Beside the above prothrombotic effects, it is involved in limiting thrombus growth by down-regulating platelet adhesion to fibrin. Elevated FXIII level seems to be a gender-specific risk factor of both coronary artery disease and peripheral arterial disease, it represents an increased risk only in females. The association of FXIII level with the risk of ischemic stroke and venous thromboembolism was investigated only in a few studies from which no clear conclusion could be drawn. Among the FXIII subunit polymorphisms, concerning their effect on the risk of thrombotic diseases, only FXIII-A p.Val34Leu was investigated extensively. Meta-analyses of reported data suggest that this polymorphism provides a moderate protection against coronary artery disease and venous thromboembolism, but not against ischemic stroke. Gene-gene and gene-environmental interactions might modify its effect. Further studies are required to explore the effect of other FXIII subunit polymorphism on the risk of thrombotic diseases.

Original languageEnglish
Pages (from-to)382-387
Number of pages6
JournalThrombosis Research
Volume129
Issue number3
DOIs
Publication statusPublished - Mar 2012

Fingerprint

Factor XIII
Thrombosis
Fibrin
Venous Thromboembolism
Coronary Artery Disease
Stroke
Genes
Antifibrinolytic Agents
Enzyme Precursors
Transglutaminases
Peripheral Arterial Disease
Disease Susceptibility
Fibrinolysis
Hemostasis
Thrombin
Meta-Analysis
Blood Platelets
Hemorrhage

Keywords

  • atherothrombotic disease
  • clot structure
  • factor XIII
  • factor XIII polymorphism
  • fibrin
  • venous thrombosis

ASJC Scopus subject areas

  • Hematology

Cite this

Factor XIII, clot structure, thrombosis. / Bagoly, Z.; Koncz, Zsuzsa; Hársfalvi, J.; Muszbek, L.

In: Thrombosis Research, Vol. 129, No. 3, 03.2012, p. 382-387.

Research output: Contribution to journalArticle

@article{2b8ac9b805a441abad9bfca201e941ca,
title = "Factor XIII, clot structure, thrombosis",
abstract = "Blood coagulation factor XIII (FXIII) is a tetrameric protein consisting of two catalytic A (FXIII-A) and two carrier/inhibitory B (FXIII-B) subunits. It is a zymogen, which becomes transformed into an active transglutaminase (FXIIIa) in the final phase of coagulation cascade by thrombin and Ca 2 +. FXIII is essential for hemostasis, its deficiency results in severe bleeding diathesis. FXIIIa mechanically stabilizes fibrin by cross-linking its α-, and γ-chains. It also protects newly formed fibrin from fibrinolysis, primarily by cross-linking α 2-plasmin inhibitor to fibrin. Beside the above prothrombotic effects, it is involved in limiting thrombus growth by down-regulating platelet adhesion to fibrin. Elevated FXIII level seems to be a gender-specific risk factor of both coronary artery disease and peripheral arterial disease, it represents an increased risk only in females. The association of FXIII level with the risk of ischemic stroke and venous thromboembolism was investigated only in a few studies from which no clear conclusion could be drawn. Among the FXIII subunit polymorphisms, concerning their effect on the risk of thrombotic diseases, only FXIII-A p.Val34Leu was investigated extensively. Meta-analyses of reported data suggest that this polymorphism provides a moderate protection against coronary artery disease and venous thromboembolism, but not against ischemic stroke. Gene-gene and gene-environmental interactions might modify its effect. Further studies are required to explore the effect of other FXIII subunit polymorphism on the risk of thrombotic diseases.",
keywords = "atherothrombotic disease, clot structure, factor XIII, factor XIII polymorphism, fibrin, venous thrombosis",
author = "Z. Bagoly and Zsuzsa Koncz and J. H{\'a}rsfalvi and L. Muszbek",
year = "2012",
month = "3",
doi = "10.1016/j.thromres.2011.11.040",
language = "English",
volume = "129",
pages = "382--387",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Factor XIII, clot structure, thrombosis

AU - Bagoly, Z.

AU - Koncz, Zsuzsa

AU - Hársfalvi, J.

AU - Muszbek, L.

PY - 2012/3

Y1 - 2012/3

N2 - Blood coagulation factor XIII (FXIII) is a tetrameric protein consisting of two catalytic A (FXIII-A) and two carrier/inhibitory B (FXIII-B) subunits. It is a zymogen, which becomes transformed into an active transglutaminase (FXIIIa) in the final phase of coagulation cascade by thrombin and Ca 2 +. FXIII is essential for hemostasis, its deficiency results in severe bleeding diathesis. FXIIIa mechanically stabilizes fibrin by cross-linking its α-, and γ-chains. It also protects newly formed fibrin from fibrinolysis, primarily by cross-linking α 2-plasmin inhibitor to fibrin. Beside the above prothrombotic effects, it is involved in limiting thrombus growth by down-regulating platelet adhesion to fibrin. Elevated FXIII level seems to be a gender-specific risk factor of both coronary artery disease and peripheral arterial disease, it represents an increased risk only in females. The association of FXIII level with the risk of ischemic stroke and venous thromboembolism was investigated only in a few studies from which no clear conclusion could be drawn. Among the FXIII subunit polymorphisms, concerning their effect on the risk of thrombotic diseases, only FXIII-A p.Val34Leu was investigated extensively. Meta-analyses of reported data suggest that this polymorphism provides a moderate protection against coronary artery disease and venous thromboembolism, but not against ischemic stroke. Gene-gene and gene-environmental interactions might modify its effect. Further studies are required to explore the effect of other FXIII subunit polymorphism on the risk of thrombotic diseases.

AB - Blood coagulation factor XIII (FXIII) is a tetrameric protein consisting of two catalytic A (FXIII-A) and two carrier/inhibitory B (FXIII-B) subunits. It is a zymogen, which becomes transformed into an active transglutaminase (FXIIIa) in the final phase of coagulation cascade by thrombin and Ca 2 +. FXIII is essential for hemostasis, its deficiency results in severe bleeding diathesis. FXIIIa mechanically stabilizes fibrin by cross-linking its α-, and γ-chains. It also protects newly formed fibrin from fibrinolysis, primarily by cross-linking α 2-plasmin inhibitor to fibrin. Beside the above prothrombotic effects, it is involved in limiting thrombus growth by down-regulating platelet adhesion to fibrin. Elevated FXIII level seems to be a gender-specific risk factor of both coronary artery disease and peripheral arterial disease, it represents an increased risk only in females. The association of FXIII level with the risk of ischemic stroke and venous thromboembolism was investigated only in a few studies from which no clear conclusion could be drawn. Among the FXIII subunit polymorphisms, concerning their effect on the risk of thrombotic diseases, only FXIII-A p.Val34Leu was investigated extensively. Meta-analyses of reported data suggest that this polymorphism provides a moderate protection against coronary artery disease and venous thromboembolism, but not against ischemic stroke. Gene-gene and gene-environmental interactions might modify its effect. Further studies are required to explore the effect of other FXIII subunit polymorphism on the risk of thrombotic diseases.

KW - atherothrombotic disease

KW - clot structure

KW - factor XIII

KW - factor XIII polymorphism

KW - fibrin

KW - venous thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84857788871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857788871&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2011.11.040

DO - 10.1016/j.thromres.2011.11.040

M3 - Article

VL - 129

SP - 382

EP - 387

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 3

ER -